9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 27

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.,  to evaluate the effect of multiple dosing of TargomiRs,  to detect early signs of efficacy, QOL assessment

Interventions: TargomiRs,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 4, 2017

Completion Date: January 4, 2017

Last  Posted Date: April 7, 2017

Location: Concord Repatriation General Hospital, Sydney, New South Wales, Australia

Website Link: https://ClinicalTrials.gov/show/NCT02369198

Was this article helpful?
Dislike 0